Fiche publication
Date publication
septembre 2024
Journal
Expert opinion on biological therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Sequier L, Caron B, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
The approval of biosimilars in the management of inflammatory bowel diseases (IBDs) has offered an answer to a growing concern about healthcare costs, and availability of treatments. Several studies have been conducted to demonstrate proof of biosimilars effectiveness as treatment in Crohn's disease (CD).
Mots clés
Adalimumab, Crohn’s disease, biosimilar, effectiveness, inflammatory bowel disease, infliximab
Référence
Expert Opin Biol Ther. 2024 09 13;:1-25
